- Home
- KPRX vs ATCH Comparison
KPRX vs ATCH Comparison
Compare KPRX & ATCH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KPRX
- ATCH
- Stock Information
- Founded
- KPRX 1998
- ATCH 2022
- Country
- KPRX United States
- ATCH United States
- Employees
- KPRX N/A
- ATCH N/A
- Industry
- KPRX Biotechnology: In Vitro & In Vivo Diagnostic Substances
- ATCH
- Sector
- KPRX Health Care
- ATCH
- Exchange
- KPRX Nasdaq
- ATCH Nasdaq
- Market Cap
- KPRX 9.2M
- ATCH 9.0M
- IPO Year
- KPRX N/A
- ATCH N/A
- Fundamental
- Price
- KPRX $2.75
- ATCH $0.39
- Analyst Decision
- KPRX Strong Buy
- ATCH
- Analyst Count
- KPRX 1
- ATCH 0
- Target Price
- KPRX $10.00
- ATCH N/A
- AVG Volume (30 Days)
- KPRX 35.6K
- ATCH 121.0M
- Earning Date
- KPRX 11-07-2025
- ATCH 11-14-2025
- Dividend Yield
- KPRX N/A
- ATCH N/A
- EPS Growth
- KPRX N/A
- ATCH N/A
- EPS
- KPRX N/A
- ATCH 0.14
- Revenue
- KPRX N/A
- ATCH $10,856,612.00
- Revenue This Year
- KPRX N/A
- ATCH N/A
- Revenue Next Year
- KPRX N/A
- ATCH N/A
- P/E Ratio
- KPRX N/A
- ATCH $2.97
- Revenue Growth
- KPRX N/A
- ATCH 171.31
- 52 Week Low
- KPRX $2.25
- ATCH $0.14
- 52 Week High
- KPRX $4.18
- ATCH $26.94
- Technical
- Relative Strength Index (RSI)
- KPRX 55.26
- ATCH 46.19
- Support Level
- KPRX $2.67
- ATCH $0.45
- Resistance Level
- KPRX $2.89
- ATCH $0.53
- Average True Range (ATR)
- KPRX 0.11
- ATCH 0.20
- MACD
- KPRX 0.02
- ATCH -0.06
- Stochastic Oscillator
- KPRX 70.26
- ATCH 0.82
About KPRX Kiora Pharmaceuticals Inc.
Kiora Pharmaceuticals Inc is a clinical-stage biotechnology company developing and commercializing products for the treatment of orphan retinal diseases. As part of its development, KIO-301 is being studied for the treatment of retinitis pigmentosa, choroideremia, and Stargardt disease. It is a molecular photoswitch that has the potential to restore vision in patients with inherited and/or age-related retinal degeneration. KIO-104 is being developed for the treatment of posterior non-infectious uveitis. It is a next-generation, non-steroidal, immuno-modulatory, and small-molecule inhibitor of dihydroorotate dehydrogenase.
About ATCH AtlasClear Holdings Inc. Common Stock
AtlasClear Holdings Inc is a fintech company. Its goal is to build a cutting-edge technology-enabled financial services firm that would create a more efficient platform for trading, clearing, settlement, and banking of evolving and innovative financial products with a focus on financial services firms. It is a fintech-driven business-to-business platform that expects to power innovation in fintech, investing, and trading. The company believes it is positioned to provide a modern, mission-critical suite of solutions to its clients, enabling them to reduce their transaction costs and compete more effectively in their businesses.